April 27, 2016 β Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering from post-thrombotic syndrome (PTS) associated with venous outflow obstruction. The stent delivery system allows the physician to deploy a venous stent beginning at the peripheral end of the common femoral vein. The stent system received CE Marking on April 1, 2016.
"Frequently, in patients with extensive venous outflow obstruction causing post-thrombotic syndrome, it is necessary to extend the stents below the inguinal ligament to cover the entirety of the common femoral vein. In these cases, accurate stent placement is essential to maintain inflow to the stent system from both the profunda and femoral veins," said Stephen Black, M.D., consultant vascular surgeon, Guy's and St. Thomas' NHS Foundation Trust, London U.K., who performed the procedure. "It is encouraging to see the team at Veniti and others in industry working with physicians to develop new products like the Vici Verto Venous Stent, which address the specific needs of the physicians treating venous disease."
PTS is a complication of deep vein thrombosis, which affects more than 1.4 million people across the United States and Western Europe each year. It is estimated that 20-50 percent of the people who have had a deep vein thrombosis will develop PTS, which can have devastating, long-term consequences affecting the quality of life for the thousands of people who suffer from the condition. Symptoms include progressive leg pain and swelling, leg heaviness and skin changes. Physicians treat the obstructive component of PTS through minimally-invasive endovascular stenting procedures. The VIRTUS Trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption to evaluate the safety and efficacy of the Vici Venous Stent for the treatment of chronic iliofemoral venous outflow obstruction.
For more information: www.veniti.com
November 06, 2019 
